Antibody-Drug Conjugate Fails to Improve Survival in Metastatic Lung Cancer When Added to Immunotherapy
Source Summary
A large randomized trial found that adding the antibody-drug conjugate sacituzumab govitecan (Trodelvy) to immunotherapy did not improve survival in patients with metastatic non-small cell lung cancer. The study measured median progression-free survival as a primary endpoint.
Why it matters
The trial result indicates that this combination approach does not provide a survival benefit for metastatic NSCLC patients, informing treatment decisions in this advanced cancer setting.
